Display options
Cite
Dodu JC, Moncayo RK, Damaj MI, et al. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. J Pharmacol Exp Ther. 2021;380(1):1-14doi: 10.1124/jpet.121.000723.
Dodu, J. C., Moncayo, R. K., Damaj, M. I., Schlosburg, J. E., Akbarali, H. I., O'Brien, L. D., Kendall, D. A., Wu, Z., Lu, D., & Lichtman, A. H. (2022). The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. The Journal of pharmacology and experimental therapeutics, 380(1), 1-14. https://doi.org/10.1124/jpet.121.000723
Dodu, Julien C, et al. "The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice." The Journal of pharmacology and experimental therapeutics vol. 380,1 (2022): 1-14. doi: https://doi.org/10.1124/jpet.121.000723
Dodu JC, Moncayo RK, Damaj MI, Schlosburg JE, Akbarali HI, O'Brien LD, Kendall DA, Wu Z, Lu D, Lichtman AH. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. J Pharmacol Exp Ther. 2022 Jan;380(1):1-14. doi: 10.1124/jpet.121.000723. Epub 2021 Oct 08. PMID: 34625464.
Copy Download .nbib Format: NLM
Share it on

J Pharmacol Exp Ther. 2022 Jan;380(1):1-14. doi: 10.1124/jpet.121.000723. Epub 2021 Oct 08.

The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.

The Journal of pharmacology and experimental therapeutics

Julien C Dodu, Rebecca K Moncayo, M Imad Damaj, Joel E Schlosburg, Hamid I Akbarali, Lesley D O'Brien, Debra A Kendall, Zhixing Wu, Dai Lu, Aron H Lichtman

Affiliations

  1. Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.) [email protected].
  2. Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.).

PMID: 34625464 DOI: 10.1124/jpet.121.000723

Abstract

Opioid use disorder reflects a major public health crisis of morbidity and mortality in which opioid withdrawal often contributes to continued use. However, current medications that treat opioid withdrawal symptoms are limited by their abuse liability or lack of efficacy. Although cannabinoid 1 (CB

Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Publication Types